Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Saved in:
| Title: | Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. |
|---|---|
| Authors: | Beernink JM; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Mosterd CM; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands., Scholtes RA; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands., Caldwell-McGee A; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Casillas D; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Driscoll L; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Greasley PJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal, Sweden., Karlsson C; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hammarstedt A; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sridhar VS; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Muskiet MHA; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands., Laverman GD; Department of Internal Medicine, ZGT Hospital, Almelo and Hengelo, The Netherlands., Cherney DZI; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Bjornstad P; Division of Metabolism, Endocrinology and Metabolism, Department of Medicine, University of Washington, Seattle, Washington, USA., van Raalte DH; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands.; Amsterdam Cardiovascular Sciences, VU University, Amsterdam, The Netherlands., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Aug; Vol. 27 (8), pp. 4415-4426. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Clinical Trial, Phase IV; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40444388 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Beernink+JM%22">Beernink JM</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Jongs+N%22">Jongs N</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mosterd+CM%22">Mosterd CM</searchLink>; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Scholtes+RA%22">Scholtes RA</searchLink>; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Caldwell-McGee+A%22">Caldwell-McGee A</searchLink>; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Casillas+D%22">Casillas D</searchLink>; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Driscoll+L%22">Driscoll L</searchLink>; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Greasley+PJ%22">Greasley PJ</searchLink>; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal, Sweden.<br /><searchLink fieldCode="AU" term="%22Karlsson+C%22">Karlsson C</searchLink>; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Hammarstedt+A%22">Hammarstedt A</searchLink>; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Sridhar+VS%22">Sridhar VS</searchLink>; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Muskiet+MHA%22">Muskiet MHA</searchLink>; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Laverman+GD%22">Laverman GD</searchLink>; Department of Internal Medicine, ZGT Hospital, Almelo and Hengelo, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Cherney+DZI%22">Cherney DZI</searchLink>; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Bjornstad+P%22">Bjornstad P</searchLink>; Division of Metabolism, Endocrinology and Metabolism, Department of Medicine, University of Washington, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22van+Raalte+DH%22">van Raalte DH</searchLink>; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands.; Amsterdam Cardiovascular Sciences, VU University, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Heerspink+HJL%22">Heerspink HJL</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100883645%22">Diabetes, obesity & metabolism</searchLink> [Diabetes Obes Metab] 2025 Aug; Vol. 27 (8), pp. 4415-4426. <i>Date of Electronic Publication: </i>2025 May 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase IV; Journal Article; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100883645 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1463-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214628902%22">14628902 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Obes Metab <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40444388 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/dom.16478 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 4415 Titles: – TitleFull: Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Beernink JM – PersonEntity: Name: NameFull: Jongs N – PersonEntity: Name: NameFull: Mosterd CM – PersonEntity: Name: NameFull: Scholtes RA – PersonEntity: Name: NameFull: Caldwell-McGee A – PersonEntity: Name: NameFull: Casillas D – PersonEntity: Name: NameFull: Driscoll L – PersonEntity: Name: NameFull: Greasley PJ – PersonEntity: Name: NameFull: Karlsson C – PersonEntity: Name: NameFull: Hammarstedt A – PersonEntity: Name: NameFull: Sridhar VS – PersonEntity: Name: NameFull: Muskiet MHA – PersonEntity: Name: NameFull: Laverman GD – PersonEntity: Name: NameFull: Cherney DZI – PersonEntity: Name: NameFull: Bjornstad P – PersonEntity: Name: NameFull: van Raalte DH – PersonEntity: Name: NameFull: Heerspink HJL IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2025 Aug Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1463-1326 Numbering: – Type: volume Value: 27 – Type: issue Value: 8 Titles: – TitleFull: Diabetes, obesity & metabolism Type: main |
| ResultId | 1 |
